ZB-716
- Generic Name
- ZB-716
ER+/HER2- Locally Advanced or Metastatic Breast Cancer (ENZENO Study)
Phase 1
- Conditions
- HER2-NegativeEstrogen Receptor-PositiveMetastatic Breast CancerLocally Advanced Breast Cancer
- Interventions
- First Posted Date
- 2020-12-17
- Last Posted Date
- 2022-03-22
- Lead Sponsor
- EnhancedBio USA Inc.
- Target Recruit Count
- 106
- Registration Number
- NCT04669587
- Locations
- 🇺🇸
Swedish Cancer Institute, Seattle, Washington, United States
🇰🇷CHA Bundang Medical Center, CHA University, Seongnam-si, Korea, Republic of
🇰🇷Kangbuk Samsung Hospital, Seoul, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath